Recombinant Human Anti-CD3 x Human Anti-FOLR1 Bispecific Antibody (Tandem scFv-Fc) (BSFVF-H258)

Recombinant Anti-CD3 x Anti-FOLR1 Bispecific Antibody (Tandem scFv-Fc) is designed to be expressed as a homodimer, which has 2+2 antigen-binding valency. This format consists of one Fc region and two tandem scFv fragments, in which the anti-CD3/FOLR1 tandem scFv is fused to the Fc domain. The engineered fragment format is used to extend the half-life. This BsAb can retarget T cells to tumor cells. It is designed for the research of Ovarian cancer; Solid tumors therapy.

Datasheet INQUIRY

Specifications

Targets

CD3 & FOLR1

Type

Constant Domain-extended Bispecific Fragments

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Ovarian cancer; Solid tumors

Targets

Target 1

CD3

Gene ID

916

UniProt ID

P07766

Alternative Names

CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3

Target 2

FOLR1

Gene ID

2348

UniProt ID

A0A024R5H1

Alternative Names

FOLR1; folate receptor 1 (adult); FBP; FOLR; folate receptor alpha; folate receptor 1; FR-alpha; KB cells FBP; folate binding protein; folate receptor, adult; adult folate-binding protein; ovarian tumor-associated antigen MOv18

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CD3 x Human Anti-FOLR1 Bispecific Antibody (Tandem scFv-Fc) (BSFVF-H258). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-CD3 x Human Anti-FOLR1 Bispecific Antibody (Tandem scFv-Fc) (CAT#: BSFVF-H258)

Specifications

Targets

Customer Reviews and Q&As